title: Nedaplatin or oxaliplatin combined with paclitaxel and docetaxel as first-line treatment for patients with advanced non-small cell lung cancer.
abstract: BACKGROUND
  Both nedaplatin and oxaliplatin combined with paclitaxel or docetaxel have demonstrated potent activity in advanced non-small cell lung cancer (NSCLC) patients, but there is no study comparing the difference between these 2 chemotherapy regimens. The aim of this study was to evaluate and compare the efficacy and safety between the combination chemotherapy of nedaplatin or oxaliplatin plus paclitaxel and docetaxel in patients with advanced NSCLC.
  
  
  METHODS
  We retrospectively reviewed patients with stage III-IV unresectable NSCLC from 1 January 2010 to 31 December 2013 at Southwest Hospital. They all received nedaplatin (80 mg/m2, nedaplatin group) or oxaliplatin (130 mg/m2, oxaliplatin group) combined with paclitaxel (175 mg/m2) or docetaxel (75 mg/m2) as first-line treatment.
  
  
  RESULTS
  There are 174 patients enrolled - 123 patients in the nedaplatin group and 51 patients in the oxaliplatin group. The objective response rates were 47.3% and 34.1% and the disease control rates were 87.5% and 79.5% in nedaplatin and oxaliplatin groups, respectively. The progression-free survival time was 10.4 months and 9.6 months (p=0.722) and the overall survival time was 18.5 months and 25.5 months in the nedaplatin and oxaliplatin groups, respectively (p=0.09). Total toxicity was greater in the oxaliplatin group (p=0.008), but there is no significant difference among ¾ grade adverse events between the 2 groups (P=0.595).
  
  
  CONCLUSIONS
  The effect of nedaplatin plus paclitaxel and docetaxel is the same as oxaliplatin plus paclitaxel and docetaxel, and the toxicity of nedaplatin is well tolerate as first-line treatment for patients with advanced NSCLC.
authors.affiliation: Department of Oncology, Southwest Hospital, Third Military Medical University, Chongqing, China (mainland).
authors.forename: Keqian
authors.initials: K
authors.lastname: Zhang
authors.affiliation: Department of Oncology, Southwest Hospital, Third Military Medical University, Chongqing, China (mainland).
authors.forename: Hong
authors.initials: H
authors.lastname: Qin
authors.affiliation: Department of Oncology, Southwest Hospital, Third Military Medical University, Chongqing, China (mainland).
authors.forename: Feng
authors.initials: F
authors.lastname: Pan
authors.affiliation: Department of Oncology, Qianjiang Central Hospital, Qianjiang, China (mainland).
authors.forename: Enqiang
authors.initials: E
authors.lastname: Liu
authors.affiliation: Department of Oncology, Southwest Hospital, Third Military Medical University, Chongqing, China (mainland).
authors.forename: Houjie
authors.initials: H
authors.lastname: Liang
authors.affiliation: Department of Oncology, Southwest Hospital, Third Military Medical University, Chongqing, China (mainland).
authors.forename: Zhihua
authors.initials: Z
authors.lastname: Ruan
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D000077150:Oxaliplatin; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D009944:Organoplatinum Compounds; D043823:Taxoids; D000077150:Oxaliplatin; D000077143:Docetaxel; C053989:nedaplatin; D017239:Paclitaxel